RegeneRx

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

Our mission is to develop regenerative and restorative medicines to protect and repair tissues and organs to improve the quality of life.

Our vision is to bring new regenerative and restorative therapies to the global healthcare market.

RegeneRx and its management have received various awards and recognition for their accomplishments, including the Ernst & Young Emerging Growth Company of the Year Award, the Rodman & Renshaw Annual Healthcare Conference's Most Promising Healthcare Company, and various awards for customer service excellence and financial performance.